In a further longitudinal study, the same investigators found that the initiation of DMARDs in combination with pulsed corticosteroids, which were employed only at the onset and as bridge therapy to accelerate the DMARD response, yielded an improvement of insulin sensitivity and a reduction in atherogenic dyslipidemia [86]. The gene discussed is INS; the disease is metabolic syndrome.